Sailesh Konda, MD; Wen Chen, MD; Harold R. Minus, MD
Dr. Konda is from the Department of Dermatology, Loma Linda University Medical Center, California. Dr. Chen is from the Department of Pathology and Dr. Minus is from the Department of Dermatology, both at the Washington DC VA Medical Center.
The authors report no conflict of interest.
Correspondence: Sailesh Konda, MD, Department of Dermatology, Loma Linda University Medical Center, 11370 Anderson St, Ste 2600, Loma Linda, CA 92354 (skonda@llu.edu).
The most effective treatment of EMPD is margin-controlled surgical excision. High local recurrence rates may be due to irregular margins, multicentricity, and the tendency of EMPD to involve clinically normal-appearing skin. Hendi et al8 noted that EMPD may actually be unifocal with subclinical fingerlike projections extending beyond the main body of the tumor, requiring CK7 immunostaining for visualization to ensure complete margin control. The recurrence rate after standard surgical excision is 33% to 60%. The recurrence rate after excision via Mohs micrographic surgery is 16% for primary EMPD and 50% for recurrent EMPD.9 Other treatment modalities include radiotherapy, topical chemotherapy with 5-fluorouracil or imiquimod, and photodynamic therapy.10-13 Combined systemic chemotherapy with trastuzumab and paclitaxel can be considered for the treatment of ERBB2-positive EMPD.14
For patients with chronic genital or perianal lesions that are unresponsive to treatment, dermatologists should maintain a high index of suspicion for EMPD. If a patient is diagnosed with EMPD, a full-body skin examination should be performed with palpation of all lymph nodes. Imaging studies directed at the anatomic location of the involved skin should be utilized to search for an underlying internal malignancy.